| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3282501 | Clinical Gastroenterology and Hepatology | 2013 | 6 Pages |
Abstract
On the basis of a post hoc analysis of data from the T72 clinical trial on the effect of infliximab in pediatric patients with UC, the PUCAI was no less predictive of sustained remission than mucosal healing at week 8, and both were superior to CRP level. Routine endoscopic evaluation in children with UC who are in complete clinical remission (ie, PUCAI <10 points) may not be necessary.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Dan Turner, Anne M. Griffiths, Gigi Veerman, Jewel Johanns, Lakshmi Damaraju, Marion Blank, Jeffrey Hyams,